Generic substitution of antiepileptic drugs

References

• Forsgren L, Beghi E, Oun A, Sillanpaa M. The epidemiology of epilepsy in Europe – a systematic review. Eur. J. Neurol.12(4), 245–253 (2005).
   PubMed Web of Science ®Google Scholar
• Kobau R, Zahran H, Thurman DJ et al. Epilepsy surveillance among adults – 19 States, Behavioral Risk Factor Surveillance System, 2005. MMWR Surveill. Summ.57(6), 1–20 (2008).
   PubMedGoogle Scholar
• Sander JW. The epidemiology of epilepsy revisited. Curr. Opin. Neurol.16(2), 165–170 (2003).
   PubMed Web of Science ®Google Scholar
• French JA, Kanner AM, Bautista J et al. Efficacy and tolerability of the new antiepileptic drugs, II: treatment of refractory epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia45(5), 410–423 (2004).
   PubMedGoogle Scholar
• Kesselheim AS, Stedman MR, Bubrick EJ et al. Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis. Drugs70(5), 605–621 (2010).
   PubMed Web of Science ®Google Scholar
• Guberman A, Corman C. Generic substitution for brand name antiepileptic drugs: a survey. Can. J. Neurol. Sci.27(1), 37–43 (2000).
   PubMedGoogle Scholar
• Berg MJ, Gross RA, Haskins LS, Zingaro WM, Tomaszewski KJ. Generic substitution in the treatment of epilepsy: patient and physician perceptions. Epilepsy Behav.13(4), 693–699 (2008).
   PubMed Web of Science ®Google Scholar
• Håkonsen H, Eilertsen M, Borge H, Toverud EL. Generic substitution: additional challenge for adherence in hypertensive patients? Curr. Med. Res. Opin.25(10), 2515–2521 (2009).
   PubMed Web of Science ®Google Scholar
• Chapman RH, Benner JS, Girase P et al. Generic and therapeutic statin switches and disruptions in therapy. Curr. Med. Res. Opin.25(5), 1247–1260 (2009).
   PubMed Web of Science ®Google Scholar
• Crawford P, Feely M, Guberman A, Kramer G. Are there potential problems with generic substitution of antiepileptic drugs? A review of issues. Seizure15(3), 165–176 (2006).
   PubMed Web of Science ®Google Scholar
• Duh MS, Paradis PE, Latremouille-Viau D et al. The risks and costs of multiple-generic substitution of topiramate. Neurology72(24), 2122–2129 (2009).
   PubMed Web of Science ®Google Scholar
• Stokes T, Shaw EJ, Juarez-Garcia A, Camosso-Stefinovic J, Baker R. Clinical Guidelines and Evidence Review for the Epilepsies: Diagnosis and Management in Adults and Children in Primary and Secondary Care. Royal College of General Practitioners, London, UK (2004).
   Google Scholar
• American Academy of Neurology. Assessment: generic substitution for antiepileptic medication. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology40(11), 1641–1643 (1990).
   PubMed Web of Science ®Google Scholar
• Liow K, Barkley GL, Pollard JR, Harden CL, Bazil CW. Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy. Neurology68(16), 1249–1250 (2007).
   PubMed Web of Science ®Google Scholar
• Endrenyi L, Midha KK. Individual bioequivalence – has its time come? Eur. J. Pharm. Sci.6(4), 271–278 (1998).
   Google Scholar
• Bialer M, Midha KK. Generic products of antiepileptic drugs: a perspective on bioequivalence and interchangeability. Epilepsia51(6), 941–950 (2010).
   PubMed Web of Science ®Google Scholar
• Tothfalusi L, Speidl S, Endrenyi L. Exposure–response analysis reveals that clinically important toxicity difference can exist between bioequivalent carbamazepine tablets. Br. J. Clin. Pharmacol.65(1), 110–122 (2007).
   Google Scholar
• Cloyd JC, Marino S, Birnbaum AK. Factors affecting antiepileptic drug pharmacokinetics in community-dwelling elderly. Int. Rev. Neurobiol.81, 201–210 (2007).
   PubMed Web of Science ®Google Scholar
• Gidal BE. Drug absorption in the elderly: biopharmaceutical considerations for the antiepileptic drugs. Epilepsy Res.68(Suppl. 1), S65–S69 (2006).
   PubMed Web of Science ®Google Scholar
• Gilman JT, Duchowny M, Campo AE. Pharmacokinetic considerations in the treatment of childhood epilepsy. Paediatr. Drugs5(4), 267–277 (2003).
   Google Scholar
• Battino D, Estienne M, Avanzini G. Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate. Clin. Pharmacokinet.29(5), 341–369 (1995).
   PubMed Web of Science ®Google Scholar
• Battino D, Estienne M, Avanzini G. Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part I: phenobarbital, primidone, valproic acid, ethosuximide and mesuximide. Clin. Pharmacokinet.29(4), 257–286 (1995).
   PubMed Web of Science ®Google Scholar
• Lesser RP, Irace P, Kutt H et al. Enhanced gastrointestinal excretion of phenytoin in a patient with Crohn’s disease. Epilepsia25(3), 302–307 (1984).
   Google Scholar
• Birnbaum AK. Pharmacokinetics of antiepileptic drugs in elderly nursing home residents. Int. Rev. Neurobiol.81, 211–220 (2007).
   Google Scholar
• Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol.2(6), 347–356 (2003).
   PubMed Web of Science ®Google Scholar
• Perucca E. Clinical pharmacology and therapeutic use of the new antiepileptic drugs. Fundam. Clin. Pharmacol.15(6), 405–417 (2001).
   PubMed Web of Science ®Google Scholar
• Endrenyi L, Tothfalusi L. Do regulatory bioequivalence requirements adequately reflect the therapeutic equivalence of modified-release drug products? J. Pharm. Pharm. Sci.13(1), 107–113 (2010).
   Google Scholar
• Krauss GL, Davit BM, Caffo BS et al. Comparing bioequivalence of generic antiepilepsy drugs (AEDs). Neurology74(Suppl. 2), Abstract A303 (2010).
   Google Scholar
• Meyer MC, Straughn AB, Mhatre RM, Shah VP, Williams RL, Lesko LJ. The relative bioavailability and in vivo–in vitro correlations for four marketed carbamazepine tablets. Pharm. Res.15(11), 1787–1791 (1998).
   PubMed Web of Science ®Google Scholar
• Meyer MC, Straughn AB, Jarvi EJ, Wood GC, Pelsor FR, Shah VP. The bioinequivalence of carbamazepine tablets with a history of clinical failures. Pharm. Res.9(12), 1612–1616 (1992).
   PubMed Web of Science ®Google Scholar
• Silpakit O, Amornpichetkoon M, Kaojarern S. Comparative study of bioavailability and clinical efficacy of carbamazepine in epileptic patients. Ann. Pharmacother.31(5), 548–552 (1997).
   PubMed Web of Science ®Google Scholar
• Soryal I, Richens A. Bioavailability and dissolution of proprietary and generic formulations of phenytoin. J. Neurol. Neurosurg. Psychiatry55(8), 688–691 (1992).
   Web of Science ®Google Scholar
• Feely M, Crawford P, Kramer G, Guberman A. Risk management in epilepsy: generic substitution and continuity of supply. Eur. J. Hosp. Pharm. Sci.11(4), 83–87 (2005).
   Google Scholar
• Chuang K, Krauss GL, Cao YJ. Evaluating FDA bioequivalence standards for generic carbamazepine formulations. Presented at: AAN 61st Annual Meeting. Seattle, WA, USA, 25 April–2 May 2009 (Poster #P05 085).
   Google Scholar
• European Parliament. Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 amending Directive 2001/83/EC on the Community Code Relating to Medicinal Products for Human Use. European Parliament, Strasbourg, France (2004).
   Google Scholar
• Schmidt D. Strategies to prevent overtreatment with antiepileptic drugs in patients with epilepsy. Epilepsy Res.52(1), 61–69 (2002).
   Google Scholar
• Bauer J, Kronisch C. [Medical treatment of epilepsy: hidden dimensions]. Nervenarzt80(4), 386–398 (2009).
   Google Scholar
• Lloyd A, McIntosh E, Price M. The importance of drug adverse effects compared with seizure control for people with epilepsy: a discrete choice experiment. Pharmacoeconomics23(11), 1167–1181 (2005).
   PubMed Web of Science ®Google Scholar
• Wilner AN. Physicians underestimate the frequency of generic carbamazepine substitution: results of a survey and review of the problem. Epilepsy Behav.3(6), 522–525 (2002).
   Google Scholar
• IMS Health. What Is The Effect of Price Discount Contracts on Routine Care?. IMS HEALTH GmbH & Co. OHG, Frankfurt/Main (2010).
   Google Scholar
• Pawloski M, Kerling F, Hercksen I et al. Interim analysis of an ongoing prospective study: use of lamotrigine generic drugs: experiences of the Epilepsy Center Erlangen. Presented at: 27th International Epilepsy Congress. Singapore, 8–12 July (2007).
   Google Scholar
• LeLorier J, Duh MS, Paradis PE et al. Clinical consequences of generic substitution of lamotrigine for patients with epilepsy. Neurology70(22 Pt 2), 2179–2186 (2008).
   PubMed Web of Science ®Google Scholar
• Paradis PE, Latremouille-Viau D, Moore Y et al. Projected economic impact of clinical findings of generic entry of topiramate on G4 European countries. Curr. Med. Res. Opin.25(7), 1793–1805 (2009).
   PubMed Web of Science ®Google Scholar
• Paradis PE, Latrémouille-Viau D, Lefebvre P et al. Clinical consequences of generic substitution of topiramate. Presented at: 28th International Epilepsy Congress (ILAE). Budapest, Hungary, 28 June – 2 July (2009) (Poster P184).
   Google Scholar
• Labiner DM, Paradis PE, Manjunath R et al. Generic antiepileptic drugs and associated medical resource utilization in the United States. Neurology74(20), 1566–1574 (2010).
   PubMed Web of Science ®Google Scholar
• Welty TE, Pickering PR, Hale BC, Arazi R. Loss of seizure control associated with generic substitution of carbamazepine. Ann. Pharmacother.26(6), 775–777 (1992).
   PubMed Web of Science ®Google Scholar
• Burkhardt RT, Leppik IE, Blesi K, Scott S, Gapany SR, Cloyd JC. Lower phenytoin serum levels in persons switched from brand to generic phenytoin. Neurology63(8), 1494–1496 (2004).
   PubMed Web of Science ®Google Scholar
• Gilman JT, Alvarez LA, Duchowny M. Carbamazepine toxicity resulting from generic substitution. Neurology43(12), 2696–2697 (1993).
   PubMed Web of Science ®Google Scholar
• Hartley R, Aleksandrowicz J, Ng PC, McLain B, Bowmer CJ, Forsythe WI. Breakthrough seizures with generic carbamazepine: a consequence of poorer bioavailability? Br. J. Clin. Pract.44(7), 270–273 (1990).
   Google Scholar
• MacDonald JT. Breakthrough seizure following substitution of Depakene capsules (Abbott) with a generic product. Neurology37(12), 1885 (1987).
   PubMed Web of Science ®Google Scholar
• Wyllie E, Pippenger CE, Rothner AD. Increased seizure frequency with generic primidone. JAMA258(9), 1216–1217 (1987).
   PubMed Web of Science ®Google Scholar
• Di Bonaventura C, Fattouch J, Fabbrini G, Manfredi M, Prencipe M, Giallonardo TA. Switching from branded to generic antiepileptic drugs as a confounding factor and unpredictable diagnostic pitfall in epilepsy management. Epileptic Disord.9(4), 465–466 (2007).
   Google Scholar
• Nielsen KA, Dahl M, Tommerup E, Wolf P. Comparative daily profiles with different preparations of lamotrigine: a pilot investigation. Epilepsy Behav.13(1), 127–130 (2008).
   Google Scholar
• Berg MJ, Gross RA, Tomaszewski KJ, Zingaro WM, Haskins LS. Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures. Neurology71(7), 525–530 (2008).
   PubMed Web of Science ®Google Scholar
• Andermann F, Duh MS, Gosselin A, Paradis PE. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Epilepsia48(3), 464–469 (2007).
   PubMed Web of Science ®Google Scholar
• Devine ST, Weisbart E, Barron J, Behm A. Acute epilepsy exacerbations in patients switched between A-rated anti-epileptic drugs. Curr. Med. Res. Opin.26(2), 455–463 (2010).
   PubMed Web of Science ®Google Scholar
• Wilner AN. Therapeutic equivalency of generic antiepileptic drugs: results of a survey. Epilepsy Behav.5(6), 995–998 (2004).
   PubMed Web of Science ®Google Scholar
• Biraben A, De TB, Semah F, Rouaud T. [Use of generic anti-epilepsy drugs in France: survey of neurologists and review of the literature]. Rev. Neurol. (Paris)163(4), 455–461 (2007).
   Google Scholar
• Haskins LS, Tomaszewski KJ, Crawford P. Patient and physician reactions to generic antiepileptic substitution in the treatment of epilepsy. Epilepsy Behav.7(1), 98–105 (2005).
   Google Scholar
• Krämer G, Steinhoff BJ, Feucht M, Pfäfflin M, May TW. [Experiences with generic drugs in epilepsy patients. Results of an internet-based questionnaire study in Germany, Austria, and Switzerland]. Akt. Neurol.33, 431–438 (2006).
   Web of Science ®Google Scholar
• Crawford P, Hall WW, Chappell B, Collings J, Stewart A. Generic prescribing for epilepsy: is it safe? Seizure5(1), 1–5 (1996).
   Web of Science ®Google Scholar
• McAuley JW, Chen AY, Elliott JO, Shneker BF. An assessment of patient and pharmacist knowledge of and attitudes toward reporting adverse drug events due to formulation switching in patients with epilepsy. Epilepsy Behav.14(1), 113–117 (2009).
   Google Scholar
• Papsdorf TB, Ablah E, Ram S, Sadler T, Liow K. Patient perception of generic antiepileptic drugs in the Midwestern United States. Epilepsy Behav.14(1), 150–153 (2009).
   Web of Science ®Google Scholar
• Begley CE, Famulari M, Annegers JF et al. The cost of epilepsy in the United States: an estimate from population-based clinical and survey data. Epilepsia41(3), 342–351 (2000).
   PubMed Web of Science ®Google Scholar
• Cockerell OC, Hart YM, Sander JW, Shorvon SD. The cost of epilepsy in the United Kingdom: an estimation based on the results of two population-based studies. Epilepsy Res.18(3), 249–260 (1994).
   PubMed Web of Science ®Google Scholar
• Heaney D. Epilepsy at work: evaluating the cost of epilepsy in the workplace. Epilepsia40(Suppl. 8), 44–47 (1999).
   PubMedGoogle Scholar
• Jacoby A, Buck D, Baker G, McNamee P, Graham-Jones S, Chadwick D. Uptake and costs of care for epilepsy: findings from a UK regional study. Epilepsia39(7), 776–786 (1998).
   PubMed Web of Science ®Google Scholar
• Duh MS, Cahill KE, Paradis PE, Cremieux PY, Greenberg PE. The economic implications of generic substitution of antiepileptic drugs: a review of recent evidence. Expert Opin. Pharmacother.10(14), 2317–2328 (2009).
   PubMed Web of Science ®Google Scholar
• Jobst BC, Holmes GL. Prescribing antiepileptic drugs: should patients be switched on the basis of cost? CNS Drugs18(10), 617–628 (2004).
   PubMed Web of Science ®Google Scholar
• Heaney DC, Begley CE. Economic evaluation of epilepsy treatment: a review of the literature. Epilepsia43(Suppl. 4), 10–16 (2002).
   PubMed Web of Science ®Google Scholar
• Begley CE, Beghi E. The economic cost of epilepsy: a review of the literature. Epilepsia43(Suppl. 4), 3–9 (2002).
   PubMedGoogle Scholar
• Strzelczyk A, Reese JP, Dodel R, Hamer HM. Cost of epilepsy: a systematic review. Pharmacoeconomics26(6), 463–476 (2008).
   PubMed Web of Science ®Google Scholar
• LeLorier J, Duh MS, Paradis PE et al. Economic impact of generic substitution of lamotrigine: projected costs in the US using findings in a Canadian setting. Curr. Med. Res. Opin.24(4), 1069–1081 (2008).
   PubMed Web of Science ®Google Scholar
• Duh MS, Andermann F, Paradis PE, Weiner J, Manjunath R, Cremieux PY. The economic consequences of generic substitution for antiepileptic drugs in a public payer setting: the case of lamotrigine. Dis. Manag.10(4), 216–225 (2007).
   PubMedGoogle Scholar
• Zachry WM, Doan QD, Clewell JD, Smith BJ. Case–control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes. Epilepsia50(3), 493–500 (2008).
   Google Scholar
• Helmers SL, Paradis PE, Manjunath R et al. Economic burden associated with the use of generic antiepileptic drugs in the United States. Epilepsy Behav.18(4), 437–444 (2010).
   PubMed Web of Science ®Google Scholar
• Kesselheim AS, Misono AS, Lee JL et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA300(21), 2514–2526 (2008).
   PubMed Web of Science ®Google Scholar
• de Wolf P, Brouwer WB, Rutten FF. Regulating the Dutch pharmaceutical market: improving efficiency or controlling costs? Int. J. Health Plann. Manage.20(4), 351–374 (2005).
   Google Scholar
• Tootelian DH, Royer J, Johnson RC. Providing incentives to control health care costs and remain competitive in the marketplace: a pilot study. Health Mark. Q.15(2), 87–99 (1997).
   Google Scholar
• Epilepsy Action. Position Statement – Consistency of Supply. British Epilepsy Association, Leeds, UK (2005).
   Google Scholar
• Haymarket Publishing. MIMS. Haymarket Publishing Ltd, London, UK (2006).
   Google Scholar
• Scottish Intercollegiate Guidelines Network. Diagnosis and Management of Epilepsy in Adults. A National Guideline. Royal College of Physicians, Edinburgh, UK (2003).
   Google Scholar
• Perucca E, Albani F, Capovilla G, Bernardina BD, Michelucci R, Zaccara G. Recommendations of the Italian League against Epilepsy working group on generic products of antiepileptic drugs. Epilepsia47(Suppl. 5), 16–20 (2006).
   PubMedGoogle Scholar
• Krämer G, Dennig D, Schmidt D et al. [Generics in antiepileptic drug therapy: what has to be considered?]. Akt. Neurol.32, 275–278 (2005).
   Web of Science ®Google Scholar
• LFCE. Recommendations on the Use of Generics for the Treatment of Epilepsy. French Chapter of the International League Against Epilepsy, Bron, France (2008).
   Google Scholar
• Brainwave. Submission to the Oireachtas Joint Committee on Health and Children in respect of the proposed substitution by generic AEDs (anti-epileptic drugs) of branded AEDs. Epilepsy News37, 4–5 (2008).
   Google Scholar
• AFSSAPS. Substitution of Antiepileptic Medications. Press release, Agence française de sécurité sanitaire des produits de santé, Paris, France (2008).
   Google Scholar
• Antiepileptic drugs: the drawbacks of generic substitution. Lancet Neurol.9(3), 227 (2010).
   Google Scholar
• Heaney DC, Sander JW. Antiepileptic drugs: generic versus branded treatments. Lancet Neurol.6(5), 465–468 (2007).
   PubMed Web of Science ®Google Scholar
• Manjunath R, Davis KL, Candrilli SD, Ettinger AB. Association of antiepileptic drug nonadherence with risk of seizures in adults with epilepsy. Epilepsy Behav.14(2), 372–378 (2009).
   PubMed Web of Science ®Google Scholar
• Johnston A, Stafylas P, Stergiou GS. Effectiveness, safety and cost of drug substitution in hypertension. Br. J. Clin. Pharmacol.70, 320–334 (2010).
   PubMed Web of Science ®Google Scholar
• Gagne JJ, Avorn J, Shrank WH, Schneeweiss S. Refilling and switching of antiepileptic drugs and seizure-related events. Clin. Pharmacol. Ther.88(3), 347–353 (2010).
   Google Scholar
• Liow K. Understanding patients’ perspective in the use of generic antiepileptic drugs: compelling lessons for physicians to improve physician/patient communication. BMC Neurol.9, 11 (2009).
   Google Scholar
• Hattingh HL. Pharmacists’ responsibility and potential liability regarding generic substitition. Med. Law28(4), 697–704 (2009).
   Google Scholar
• European Commission Enterprise Directorate-General. Marketing authorisation. In: Procedures for Marketing Authorisation (Volume 2A). European Commission Enterprise Directorate-General, Brussels (2006).
   Google Scholar
• Borgherini G. The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs. Clin. Ther.25(6), 1578–1592 (2003).
   PubMed Web of Science ®Google Scholar
• Nashef L, Fish DR, Garner S, Sander JW, Shorvon SD. Sudden death in epilepsy: a study of incidence in a young cohort with epilepsy and learning difficulty. Epilepsia36(12), 1187–1194 (1995).
   PubMed Web of Science ®Google Scholar
• Kitson A, Shorvon S. Clinical Standards Advisory Group. Services for Patients with Epilepsy. Department of Health, London, UK (2000).
   Google Scholar
• Shorvon SD. The epidemiology and treatment of chronic and refractory epilepsy. Epilepsia37(Suppl. 2), S1–S3 (1996).
   Google Scholar
• Hanna NJ, Black M, Sander JW et al.The National Sentinel Clinical Audit of Epilepsy-Related Death. Epilepsy – Death in the Shadows. The Stationery Office, Norwich, UK (2002).
   Google Scholar
• Epilepsy: safety, excess mortality and sudden death. Epilepsia44(Suppl. 6), 19–20 (2003).
   Google Scholar
• Schmidt D, Loscher W. Uncontrolled epilepsy following discontinuation of antiepileptic drugs in seizure-free patients: a review of current clinical experience. Acta Neurol. Scand.111(5), 291–300 (2005).
   PubMed Web of Science ®Google Scholar
• Tomson T, Walczak T, Sillanpaa M, Sander JW. Sudden unexpected death in epilepsy: a review of incidence and risk factors. Epilepsia46(Suppl. 11), 54–61 (2005).
   PubMed Web of Science ®Google Scholar